etanercept Archives

Study finds biosimilar switching policy increased biosimilar use more than new start policies

by Bioblast Editor | Feb 8, 2023 | Uncategorized

A new study published in Arthritis Care and Research found that mandatory switching policies were much more effective at driving biosimilar uptake than new start policies. The study examined 5,884 patients taking infliximab (Johnson & Johnson’s Remicade®,...

Amgen to present data on biosimilars portfolio at ACRC

by Bioblast Editor | Nov 7, 2022 | Biosimilars updates

Amgen announced that it will present data across its portfolio at the American College of Rheumatology Convergence on 10-14 November 2022, including data for Amgevita® (biosimilar adalimumab), Enbrel® (biosimilar etanercept) and Prolia® (biosimilar...

Health Canada approves Lupin’s Rymti® (biosimilar etanercept)

by Bioblast Editor | Sep 13, 2022 | Biosimilars updates

Lupin announced that Health Canada has approved Rymti® (biosimilar etanercept) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondylarthritis (including ankylosing spondylitis and non-radiographic axial...

Viatris (Mylan) seeks PBS listng for etanercept biosimilar

by Bioblast Editor | Jul 27, 2022 | Biosimilars updates

Alphapharm (Viatris’ Australian subsidiary) has its etanercept biosimilar, Nepexto®, on the agenda for the November PBAC meeting. If the PBAC recommends that Nepexto is PBS-listed, it will become the third PBS-listed etanercept product after Pfizer’s Enbrel® and...

Pfizer commences patent infringement proceedings against Samsung Bioepis, MSD, Organon and Arrow Pharmaceuticals

by Bioblast Editor | May 6, 2022 | Biosimilars updates

Pfizer commenced patent infringement proceedings in the Federal Court of Australia against Samsung Bioepis, MSD, Organon and Arrow Pharmaceuticals in relation to AU2005280034 and the supply of etanercept.